Related references
Note: Only part of the references are listed.Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia
Prajakta P. Masurkar et al.
DRUGS & AGING (2021)
2021 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2021)
Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the US Medicare Data
Dae Hyun Kim et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2020)
Sex as a Biological Variable: A 5-Year Progress Report and Call to Action
Matthew E. Arnegard et al.
JOURNAL OF WOMENS HEALTH (2020)
An empirical comparison of time-to-event models to analyse a composite outcome in the presence of death as a competing risk
Ndamonaonghenda Haushona et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression
Farid Chekani et al.
DRUG HEALTHCARE AND PATIENT SAFETY (2020)
Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
Shinji Matsunaga et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners
Rishi J. Desai et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Machine Learning Approaches to Predict 6-Month Mortality Among Patients With Cancer
Ravi B. Parikh et al.
JAMA NETWORK OPEN (2019)
A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia
Ruth Knight et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2018)
Initial Cholinesterase Inhibitor Therapy Dose and Serious Events in Older Women and Men
Paula A. Rochon et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2018)
Practical recommendations for reporting Fine-Gray model analyses for competing risk data
Peter C. Austin et al.
STATISTICS IN MEDICINE (2017)
Optimizing variance-bias trade-off in the TWANG package for estimation of propensity scores
Layla Parast et al.
HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY (2017)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study
Daniela Koller et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2016)
PSHREG: A SAS macro for proportional and nonproportional subdistribution hazards regression
Maria Kohl et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2015)
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease
G. Alva et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2015)
Concurrent Use of Stimulants and Second-Generation Antipsychotics Among Children With ADHD Enrolled in Medicaid
Pravin Kamble et al.
PSYCHIATRIC SERVICES (2015)
Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study
Murat Emre et al.
CLINICAL NEUROPHARMACOLOGY (2014)
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis
Andrea C. Tricco et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2013)
Propensity Score Methods for Confounding Control in Nonexperimental Research
M. Alan Brookhart et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2013)
A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease
Simona Gabriella Di Santo et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine A Multiple Propensity Score-Adjusted Retrospective Cohort Study
Satabdi Chatterjee et al.
DRUGS & AGING (2012)
Efficacy of cognitive enhancers for Alzheimer's disease: protocol for a systematic review and network meta-analysis
Andrea C. Tricco et al.
SYSTEMATIC REVIEWS (2012)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Use of Antipsychotic Drugs in Patients with Alzheimer's Disease Treated with Rivastigmine versus Donepezil A Retrospective, Parallel-Cohort, Hypothesis-Generating Study
Douglas W. Scharre et al.
DRUGS & AGING (2010)
The Multiple Propensity Score as Control for Bias in the Comparison of More Than Two Treatment Arms An Introduction From a Case Study in Mental Health
Marieke Dingena Spreeuwenberg et al.
MEDICAL CARE (2010)
Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors A Population-Based Cohort Study
Sudeep S. Gill et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
Harish Kavirajan et al.
LANCET NEUROLOGY (2007)
Cumulative incidence in competing risks data and competing risks regression analysis
Haesook T. Kim
CLINICAL CANCER RESEARCH (2007)
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 24-week open-label study
Keith Edwards et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
HD Quan et al.
MEDICAL CARE (2005)
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
H Kaduszkiewicz et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Propensity score estimation with boosted regression for evaluating causal effects in observational studies
DF McCaffrey et al.
PSYCHOLOGICAL METHODS (2004)
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine
DC Suh et al.
DRUGS & AGING (2004)
Centrally acting Antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine
SS Jhee et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Risk factors for adverse drug events among nursing home residents
TS Field et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Share Paper
